spacer
home > pmps > winter 2002 > the environmental impact of metered dose inhalers
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Environmental Impact of Metered Dose Inhalers

Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung diseases and are among the leading causes of morbidity and mortality in the Western world. Asthma is a reversible narrowing of the airways, combined with a chronic inflammation. For reasons largely unknown, the incidence of asthma is rapidly rising. The number of patients increases annually, and today approximately five per cent of the population of the US and Europe suffer from this disease (1-4).

COPD is a chronic inflammation and destruction of the airways. There is a progressive, non-reversible loss of lung function which will eventually lead to invalidity and death. COPD usually occurs in elderly people, of which most are smokers or former smokers (5).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Cees Winnips MD, Director of Business Development at SkyePharma AG
Cornelis 'Cees' Winnips is educated and trained as a physician and began his career in the pharmaceutical industry in 1989 with Ciba-Geigy in the Netherlands. After a short period in the medical department, he moved to the commercial side and worked as Group Product Manager.

In 1993, he relocated to Austria to head the marketing department of Ciba Austria. In 1995, he moved to the Ciba/Novartis head office in Basel, Switzerland as Manager of Business Development, and subsequently became International Product Manager for the respiratory franchise. In 1998, he joined SkyePharma as Director of Business Development.

spacer
Cees Winnips
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement